SCHEMBL20008740

SCHEMBL20008740

O=C(NCCOc1ccc(C(=O)Cl)cc1)OCc1ccccc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.71
MAPT P10636 2/20 0.71
SMN1; SMN2 Q16637 3/20 0.62
LMNA P02545 1/20 0.62
HTT P42858 1/20 0.52
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
HPGD P15428 1/20 0.49
NR4A1 P22736 1/20 0.48
NR4A2 P43354 1/20 0.48
NR4A3 Q92570 1/20 0.48
TGM2 P21980 1/20 0.47
USP2 O75604 1/20 0.47
ALOX15 P16050 1/20 0.47
TSHR P16473 1/20 0.47
MAPK1 P28482 1/20 0.47
HSD17B10 Q99714 1/20 0.47
MTNR1A P48039 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20500014 0.90 L3MBTL1 (0.74) L3MBTL1MAPTSMN1; SMN2LMNAHTT
SCHEMBL3811564 0.88 L3MBTL1 (0.80) L3MBTL1MAPTSMN1; SMN2LMNAHTT
SCHEMBL9205258 0.87 L3MBTL1 (0.75) L3MBTL1MAPTSMN1; SMN2LMNAHTT
SCHEMBL6331080 0.87 L3MBTL1 (0.71) L3MBTL1MAPTSMN1; SMN2LMNAHTT
SCHEMBL30288350 0.86 L3MBTL1 (0.77) L3MBTL1MAPTSMN1; SMN2LMNAHTT
SCHEMBL20299180 0.84 L3MBTL1 (0.79) L3MBTL1MAPTSMN1; SMN2LMNAHTT
SCHEMBL24627827 0.84 L3MBTL1 (0.70) L3MBTL1MAPTSMN1; SMN2LMNAHTT
SCHEMBL28677911 0.84 MAPT (0.78) L3MBTL1MAPTSMN1; SMN2LMNAHTT
Water SCHEMBL9210675 0.84 L3MBTL1 (0.67) L3MBTL1MAPTSMN1; SMN2LMNAHTT
SCHEMBL9272300 0.83 L3MBTL1 (0.81) L3MBTL1MAPTSMN1; SMN2LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11154549-B2 Opioid compositions resistant to overdose and abuse ELYSIUM THERAPEUTICS, INC. (US) 2021-10-26 US disclosed
US-20200093817-A1 OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE ELYSIUM THERAPEUTICS, INC. 2020-03-26 US disclosed
US-10335406-B2 Opioid compositions resistant to overdose and abuse ELYSIUM THERAPEUTICS, INC. (US) 2019-07-02 US disclosed
US-20180085366-A1 OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE ELYSIUM THERAPEUTICS, INC. 2018-03-29 US disclosed
US-20180085366-A1 OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE ELYSIUM THERAPEUTICS, INC. 2018-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200093817-A1 OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE OPRM1, OPRK1, OPRD1 L3MBTL1 1832/4885MAPT 922/4885SMN1; SMN2 1281/4885
US-20180085366-A1 OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE OPRM1, OPRK1, OPRD1 L3MBTL1 1832/4885MAPT 922/4885SMN1; SMN2 1281/4885
US-10335406-B2 Opioid compositions resistant to overdose and abuse OPRM1, OPRK1, OPRD1 L3MBTL1 1832/4885MAPT 922/4885SMN1; SMN2 1281/4885
US-11154549-B2 Opioid compositions resistant to overdose and abuse OPRM1, OPRK1, OPRD1 L3MBTL1 1832/4885MAPT 922/4885SMN1; SMN2 1281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.